Treatment Goals (QOL) | Novartis Egypt

acute-myeloid-leukemia-aml-is-type-blood-cancer-microscopic-examination-blasts-cells 1.png

As patients are living longer and are often on TKIs for years, QOL has become an important treatment goal¹

Improving/preserving QOL

Roughly 50% of patients diagnosed with CML are asymptomatic²

Symptom burden primarily related to the treatment-related AEs with TKIs can have a

Negative Impact on HRQOL⁴

and may affect a patients’ ability to stay adherent to treatment long-term at the optimal dose⁵

Minimizing AEs is an important step in helping patients achieve treatment milestones

While each TKI is associated with a distinct safety profile, there are class effects as well as AEs more commonly associated with ≥1 TKI that can impact tolerability and QOL³
AEs can also lead to treatment switching, which can have an adverse impact on survival⁷
Successful AE management can make patients more adherent to treatment, which can improve clinical outcomes and QOL⁶
Because each patient has a unique treatment experience, AE management needs to be individualized to help patients stay on treatment at the optimal dose⁵
More information is needed to guide AE risk assessment and optimize treatment selection

Fatigue, muscle, and bone pain

Gastrointestinal events

Pulmonary issues

Cardiovascular events

Thrombotic and bleeding events

Elevated lipase/pancreatitis

Cytopenias

Adapted from ref 8

AE, adverse event; CML, chronic myeloid leukemia; HRQOL, health related quality of life; QOL, quality of life; TKI, tyrosine kinase inhibitor; 1L, 1st line; 2L, 2nd line; AE, adverse event

References

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.
Eden RE, Coviello JM. Chronic myelogenous leukemia. InStatPearls [Internet] 2022 May 13. StatPearls Publishing.
Kekäle M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient preference and adherence. 2015 Dec 8:1733-40.
Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Supportive Care in Cancer. 2013 Apr;21:1097-103.
Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology 2014, the American Society of Hematology Education Program Book. 2016 Dec 2;2016(1):170-9.
Khoury HJ, Williams LA, Atallah E, Hehlmann R. Chronic myeloid leukemia: what every practitioner needs to know in 2017. American Society of Clinical Oncology Educational Book. 2017 Jan 1;37:468-79.
Kong JH, Winton EF, Heffner LT, Gaddh M, Hill B, Neely J, Hatcher A, Joseph M, Arellano M, El-Rassi F, Kim A. Outcomes of chronic phase chronic myeloid leukemia after treatment with multiple tyrosine kinase inhibitors. Journal of Clinical Medicine. 2020 May 20;9(5):1542.
Apperley JF. Chronic myeloid leukaemia. The Lancet. 2015 Apr 11;385(9976):1447-59.

Approved by Egyptian Drug Authority: HF0424OA5944/042026. Invalidation date: 20/04/2028
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg